Wed, February 13, 2013
Tue, February 12, 2013
Mon, February 11, 2013
Sun, February 10, 2013
Fri, February 8, 2013
Thu, February 7, 2013
Wed, February 6, 2013
Tue, February 5, 2013

Evan Seigerman Maintained (BIIB) at Buy with Increased Target to $185 on, Feb 8th, 2013


  Copy link into your clipboard //stocks-investing.news-articles.net/content/201 .. ith-increased-target-to-185-on-feb-8th-2013.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication
Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $175 to $185 on, Feb 8th, 2013.

Evan has made no other calls on BIIB in the last 4 months.



There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 3 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Decreased Target to $139 on, Thursday, January 3rd, 2013


This is the rating of the analyst that currently disagrees with Evan


  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $170 on, Wednesday, February 6th, 2013

Publication Contributing Sources